Human Normal Immunoglobulin
Human Normal Immunoglobulin is a sterile, highly purified solution of immunoglobulin G (IgG) antibodies derived from pooled human plasma. It provides passive immunization by replacing missing antibodies to protect against infections, and acts as an immunomodulatory agent to treat various autoimmune and inflammatory disorders.
Dosage by Body Weight
Dosage must be strictly individualized based on the specific indication, clinical response, serum IgG trough levels, and tolerability. Typically administered intravenously (IV) or subcutaneously (SC) under direct medical supervision.
- Body Weight
- Below 5 kg
- Dose
- 0.4 g/kg (approx. 1 to 2 g)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Must be calculated and administered precisely by a clinical specialist; monitor infusion rate continuously.
- Body Weight
- 5-7 kg
- Dose
- 2.0 g to 2.8 g (based on 0.4 g/kg replacement therapy)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Doses for immunomodulation (e.g., ITP) are significantly higher, up to 1 to 2 g/kg total dose.
- Body Weight
- 8-10 kg
- Dose
- 3.2 g to 4.0 g (based on 0.4 g/kg replacement therapy)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Adjust doses based on clinical response and pre-infusion IgG trough levels.
- Body Weight
- 11-15 kg
- Dose
- 4.4 g to 6.0 g (based on 0.4 g/kg replacement therapy)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Infusion rate should be started very slowly and titrated up gradually if tolerated.
- Body Weight
- 16-20 kg
- Dose
- 6.4 g to 8.0 g (based on 0.4 g/kg replacement therapy)
- Frequency
- Every 3 to 4 weeks
- Tracking Notes
- Adequate hydration must be ensured prior to and during the infusion to reduce the risk of renal adverse effects.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 0.4 g/kg (approx. 1 to 2 g) | Every 3 to 4 weeks | Must be calculated and administered precisely by a clinical specialist; monitor infusion rate continuously. |
| 5-7 kg | 2.0 g to 2.8 g (based on 0.4 g/kg replacement therapy) | Every 3 to 4 weeks | Doses for immunomodulation (e.g., ITP) are significantly higher, up to 1 to 2 g/kg total dose. |
| 8-10 kg | 3.2 g to 4.0 g (based on 0.4 g/kg replacement therapy) | Every 3 to 4 weeks | Adjust doses based on clinical response and pre-infusion IgG trough levels. |
| 11-15 kg | 4.4 g to 6.0 g (based on 0.4 g/kg replacement therapy) | Every 3 to 4 weeks | Infusion rate should be started very slowly and titrated up gradually if tolerated. |
| 16-20 kg | 6.4 g to 8.0 g (based on 0.4 g/kg replacement therapy) | Every 3 to 4 weeks | Adequate hydration must be ensured prior to and during the infusion to reduce the risk of renal adverse effects. |
Formulation
Purpose
Used for antibody replacement therapy in primary and secondary immunodeficiency diseases, and for immunomodulation in conditions like Idiopathic Thrombocytopenic Purpura (ITP), Kawasaki disease, and Guillain-Barré syndrome.
Generic Name
Human Normal ImmunoglobulinBranded Drug Names
Human Normal Immunoglobulin is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.